Integrity and transparency determine our interactions with Patient Groups
Roche is convinced that an open dialogue and transparent exchange of information with patient groups is vital.
Building and sustaining relationships with patient groups is an efficient way to get valuable insights that influence Roche’s work across therapeutic areas – from drug development to regulatory approval and reimbursement into product launch and marketing. We are increasingly partnering with patient groups on projects ranging from disease awareness campaigns to clinical trial design.
Roche works with a wide range of patient groups in a variety of different areas, e.g. oncology, viral diseases, metabolic diseases and central nervous system diseases.
Patient groups provide patients with support and information on how to live with their disease, represent patient views and campaign for change on issues that affect patients’ lives.
Different stakeholders, e.g. governments, trade associations (such as EFPIA and AdvaMed), the public and the media, call for integrity and transparency in terms of how industry interacts with patient groups and request the disclosure of financial and in-kind support provided by industry. Annually, Roche publishes the names of all patient groups it works with globally, and the support provided to them, on various channels.
Roche consistently applies high standards of conduct in its interactions with patient groups. All relationships with patient groups are based on the common values of integrity, independence, respect, equity, transparency and mutual benefit. These standards are set forth in the “Roche Good Practice Guidelines on Working with Patient Groups”.